Q2 FY2026 EarningsQ2 FY2026 results missed bottom-line expectations, with a Net Loss of $4.8M vs. the $3.6M consensus mean, and GAAP EPS of -$1.04 meeting the consensus figure. Revenue remains at $0 as the company focuses on IND-enabling activities for AKTX-101. The cash position was strengthened by $8.6M in financing, though R&D expenses rose 200% YoY to $2.1M to support development toward a planned mid-2027 Phase 1 trial.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Akari Therap(AKTX) the EBIT is -4.602 M (-47.55%), Miss estimate;the EPS is 0 (+100%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.00B47.55%
-0.00B15.42%
-0.00B32.13%
EPSExceed expectations
0100.00%
-0.5278.41%
+0.520021.59%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf